From: Genetics of Alzheimer disease in the pre- and post-GWAS era
 |  |  |  |  |  | Discovery series | Replication series |  | ||
---|---|---|---|---|---|---|---|---|---|---|
Reference | Ethnicity/Source | Samples | Study design | Genotyping platform | SNPsa | AD patients | Controls | AD patients | Controls | Follow-up criteria |
Grupe et al. [50], February 2007 | UK/US | Case control | 1 discovery (pooled DNA) and 5 replication series (1 pooled) | Gene-based putative functional polymorphisms | 17,343 (in 11,211 genes) | 380 | 396 | 1,428 | 1,666 | P < 0.075 or P < 0.1 and biology (stage 1) P < 0.15 and same risk allele (stage 2) P < 0.05 in UK1 and WU and P meta < 0.005 (stage 3) |
Coon et al. [51], April 2007 | US/The Netherlands | Case control | Single-stage study | Affymetrix 500K | 502,627 | 664 | 422 | - | - | Single-stage |
Reiman et al. [52], June 2007b | US/The Netherlands | Case control | 1 discovery and 2 replication series | Affymetrix 500K | 312,316 | 446 | 290 | 415 | 260 | All SNPs genotyped in both stages. |
Li et al. [53], January 2008 | Canada/UK | Case control | 1 discovery and 1 replication series | Affymetrix 500K | 469,438 | 753 | 736 | 418 | 249 | Top 120 SNPs |
Abraham et al. [54], September 2008 | UK | Case control | Single-stage study (first pooled, hen individual enotyping) | Illumina HumanHap300 and llumina Sentrix umanHap240S | 561,494 | 1,082 | 1,239 | - | 1,400 | Passed three criteria and could be genotyped (stage 1) ≤ 0.05 (stage 2) |
Bertram et al. [55], November 2008 | US | Family-based | 1 discovery and 3 replication series | Affymetrix 500K | 404,604 | 941 | 404 | 1,767 | 838 | Significance after weighted-Bonferroni correction |
Beecham et al. [56], January 2009 | US | Case control | 1 discovery and 1 replication series | Illumina HumanHap550 | 532,000 | 492 | 496 | 238 | 220 | Significance after FDR-BUM criteria |
Feulner et al. [57], January 2009 | Germany | Case control | Single-stage study | Illumina HumanHap550 | 555,000 | 491 | 479 | - | - | Single-stage |
Poduslo et al. [58], January 2009b | US | Family-based and case control | 1 discovery and 2 replication series | Affymetrix 500K | 469,218 | 19 (family members) | 60 (CEPH) | 140 (family members) 199 (unrelated) | 85 (unrelated) | Genome-wide significance after Bonferroni correction |
Carrasquillo et al. [59], February 2009b | US | Case control | 3 discovery and 4 replication series | Illumina HumanHap300 | 313,504 | 844 | 1,255 | 1,547 | 1,209 | 25 top SNPs |
Harold et al. [60], September 2009b | US/Europe | Case control | 13 discovery and 5 replication series | Illumina 610-quad, Illumina umanHap550, or umanHap300 | 529,205 (up to) | 3,941 | 7,848 | 2,023 | 2,340 | Genome-wide significance after Bonferroni correction + 12 other CLU/PICALM SNPs |
Lambert et al. [61], September 2009b | Europe | Case control | 1 discovery and 4 replication series (15 centers) | Illumina Human 610-Quad BeadChip | 537,029 | 2,032 | 5,328 | 3,978 | 3,297 | P < 10-5 |